Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XENE 
Xenon Pharmaceuticals Inc (XENE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: XENE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $55.23
1 Year Target Price $55.23
| 14 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.43% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.49B USD | Price to earnings Ratio - | 1Y Target Price 55.23 |
Price to earnings Ratio - | 1Y Target Price 55.23 | ||
Volume (30-day avg) 19 | Beta 1.1 | 52 Weeks Range 26.74 - 46.00 | Updated Date 06/30/2025 |
52 Weeks Range 26.74 - 46.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-04 | When Before Market | Estimate -0.8972 | Actual -0.83 |
Profitability
Profit Margin - | Operating Margin (TTM) -969.84% |
Management Effectiveness
Return on Assets (TTM) -22.03% | Return on Equity (TTM) -31.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1945981943 | Price to Sales(TTM) 331.49 |
Enterprise Value 1945981943 | Price to Sales(TTM) 331.49 | ||
Enterprise Value to Revenue 259.46 | Enterprise Value to EBITDA -11.81 | Shares Outstanding 76733600 | Shares Floating 70881895 |
Shares Outstanding 76733600 | Shares Floating 70881895 | ||
Percent Insiders 0.26 | Percent Institutions 103.59 |
Analyst Ratings
Rating 4 | Target Price 55.23 | Buy 5 | Strong Buy 14 |
Buy 5 | Strong Buy 14 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xenon Pharmaceuticals Inc
Company Overview
History and Background
Xenon Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat neurological disorders. Founded in 1996, Xenon initially focused on genetic discoveries and has since evolved into a clinical-stage company with a pipeline of novel therapies.
Core Business Areas
- Neurology: Focuses on developing therapies for neurological disorders such as epilepsy and other central nervous system diseases.
Leadership and Structure
Xenon is led by a management team with experience in drug development and commercialization. The company has a board of directors that provides strategic oversight. The structure is typical of a clinical-stage biopharmaceutical company, with functional departments responsible for research, development, clinical trials, and commercialization planning.
Top Products and Market Share
Key Offerings
- XEN1101 (active treatment of epilepsy): XEN1101 is a Kv7 potassium channel opener being developed for the treatment of epilepsy. Phase 3 trials are ongoing. There are no current market share data available, as the product is not yet approved. Competitors include established anti-epileptic drugs from companies like UCB (UCBJF), Eisai (ESALY), and generic manufacturers.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and competition from both branded and generic drugs. The neurology segment is growing due to an aging population and increasing prevalence of neurological disorders.
Positioning
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on neurology. Its competitive advantage lies in its novel drug candidates and expertise in ion channel modulation.
Total Addressable Market (TAM)
The total addressable market for epilepsy treatments is estimated to be in the billions of dollars globally. Xenon is positioned to capture a portion of this market with XEN1101 if approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Expertise in ion channel modulation
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited commercial infrastructure
- High cash burn rate
- Dependence on partnerships for funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory delays
- Competition from other pharmaceutical companies
- Patent expiration
- Generic erosion after market entry
Competitors and Market Share
Key Competitors
- UCB SA (UCBJF)
- Eisai Co., Ltd. (ESALY)
- SK Biopharmaceuticals (326030.KS)
Competitive Landscape
Xenon is a smaller company compared to larger pharmaceutical companies. The company is focusing on finding a place within the epilepsy market.
Growth Trajectory and Initiatives
Historical Growth: Xenon's growth has been driven by its drug development pipeline. Historically, growth is dependent upon achieving milestones related to the clinical trial outcome.
Future Projections: Future growth is dependent on the successful development and commercialization of XEN1101 and other pipeline candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing XEN1101 through Phase 3 clinical trials and expanding the pipeline with new drug candidates.
Summary
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing neurological therapies. The success is based on the clinical trial results, especially XEN1101. It lacks large commercial infrastructure, which is a risk. Its growth depends on funding and regulatory approvals, so investors should be cautious. It has a strong drug candidate portfolio but can be seen as a high risk, high reward company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Burnaby, BC, Canada | ||
IPO Launch date 2014-11-05 | President, CEO & Director Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.xenon-pharma.com |
Full time employees 316 | Website https://www.xenon-pharma.com | ||
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.